The impact of Ab protein dose on the pharmacokinetics of anti-PD-L1 Ab was examined using 111In-DTPA-anti-PD-L1-BC (approximately 370 kBq) at the following protein doses: 1 mg/kg (20 μg Ab), 3 mg/kg (60 μg Ab), and 10 mg/kg (200 μg Ab); the pharmacokinetics of 225Ac-DOTA-anti-PD-L1-BC (15 kBq on 3 mg/kg) were also examined (Fig. 1). This evidence concerns the gene CD274 and breast cancer.